Prestige Consumer Healthcare (PBH) Projected to Announce Earnings on Thursday

by · The Cerbat Gem

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) is expected to issue its Q2 2027 results before the market opens on Thursday, November 5th. Analysts expect Prestige Consumer Healthcare to announce earnings of $1.07 per share and revenue of $329.14 million for the quarter. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Interested persons may review the information on the company’s upcoming Q2 2027 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%. The company had revenue of $265.71 million for the quarter, compared to analysts’ expectations of $253.02 million. During the same period last year, the firm earned $0.90 EPS. The firm’s revenue for the quarter was up 6.5% on a year-over-year basis. On average, analysts expect Prestige Consumer Healthcare to post $4.56 EPS for the current fiscal year and $5.09 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Down 0.4%

PBH opened at $49.52 on Wednesday. Prestige Consumer Healthcare has a one year low of $42.62 and a one year high of $71.07. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The stock’s fifty day moving average is $48.46 and its 200-day moving average is $54.05. The company has a market capitalization of $2.35 billion, a PE ratio of 11.25, a P/E/G ratio of 1.56 and a beta of 0.30.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Zacks Research cut Prestige Consumer Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 29th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and a consensus target price of $67.67.

Read Our Latest Report on Prestige Consumer Healthcare

Prestige Consumer Healthcare Company Profile

(Get Free Report)

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.

Read More